Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Glandular Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Glandular Cell Neoplasm

Cancer Family

Glandular Cell Neoplasm

CI-CAN-00000188Explore in graph →

Non-malignant2,825 active trials43 approved drugs426 evidence items

NCIt: C7132

Overview
Statistics
Survival
Genomics166
Variants & evidence426
Drugs106
Trials10211
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (384)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 176–200 of 384 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
· J Thorac Oncol · 2014 · PMID 25521405 · validated civic_curation pubmed
ROS1 rearrangements define a unique molecular class of lung cancers.
· J Clin Oncol · 2012 · PMID 22215748 · validated civic_curation pubmed
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
· Genome Biol · 2010 · PMID 20696054 · validated civic_curation pubmed
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
· Clin Lung Cancer · 2015 · PMID 25922291 · validated civic_curation pubmed
Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response.
· Endocrinol Diabetes Metab Case Rep · 2016 · PMID 26788326 · validated civic_curation pubmed
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed
Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer.
· Cold Spring Harb Mol Case Stud · 2016 · PMID 27626067 · validated civic_curation pubmed

Showing 176–200 of 384 publications

← Previous
1
…
7
8
9
…
16
Next →

Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe.

· Hum Genet · 1996 · PMID 8707293 · validated civic_curation pubmed

Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.

· Ann Oncol · 2017 · PMID 28950338 · validated civic_curation pubmed

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.

· Clin Cancer Res · 2016 · PMID 26933125 · validated civic_curation pubmed

EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.

· J Natl Compr Canc Netw · 2017 · PMID 28874593 · validated civic_curation pubmed

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

· Am J Hum Genet · 1994 · PMID 7977367 · validated civic_curation pubmed

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.

· Clin Cancer Res · 2019 · PMID 31068372 · validated civic_curation pubmed

Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma.

· Cold Spring Harb Mol Case Stud · 2018 · PMID 29610391 · validated civic_curation pubmed

Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.

· JCO Precis Oncol · 2022 · PMID 35005993 · validated civic_curation pubmed

EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.

· Lung Cancer · 2022 · PMID 35245845 · validated civic_curation pubmed

A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report.

· Onco Targets Ther · 2021 · PMID 34163176 · validated civic_curation pubmed

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.

· JCO Precis Oncol · 2022 · PMID 35085007 · validated civic_curation pubmed

An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.

· Eur J Endocrinol · 2022 · PMID 35118995 · validated civic_curation pubmed

Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).

· Mod Pathol · 2020 · PMID 32457407 · validated civic_curation pubmed

Morphologic and Ancillary Studies of Pediatric Acinic Cell Carcinoma: A Single Institute Experience.

· Head Neck Pathol · 2023 · PMID 36169793 · validated civic_curation pubmed

EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?

· J Thorac Oncol · 2018 · PMID 29472054 · validated civic_curation pubmed

EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.

· Transl Lung Cancer Res · 2022 · PMID 35399574 · validated civic_curation pubmed

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report.

· JTO Clin Res Rep · 2024 · PMID 38525318 · validated civic_curation pubmed

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report.

· Heliyon · 2023 · PMID 38074875 · validated civic_curation pubmed